Zeng Guangqiao, Zheng Peiyan, Luo Wenting, Huang Huimin, Wei Nili, Sun Baoqing
State Key Laboratory of Respiratory Disease, Guangzhou 510120, Guangdong, China; National Clinical Research Center for Respiratory Disease, Guangzhou 510120, Guangdong, China; Guangzhou Institute of Respiratory Diseases, Guangzhou 510120, Guangdong, China; First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong, China; Guangzhou Medical University, Guangzhou 510120, Guangdong, China.
State Key Laboratory of Respiratory Disease, Guangzhou 510120, Guangdong, China; National Clinical Research Center for Respiratory Disease, Guangzhou 510120, Guangdong, China; Guangzhou Institute of Respiratory Diseases, Guangzhou 510120, Guangdong, China; First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, Guangdong, China; Guangzhou Medical University, Guangzhou 510120, Guangdong, China.
Mol Immunol. 2016 Jun;74:1-9. doi: 10.1016/j.molimm.2016.04.005. Epub 2016 Apr 22.
Longitudinal data on serum specific sIgE and sIgG4 to allergen component of Dermatophagoides pteronyssinus (Der p) during allergen immunotherapy (AIT) are limited in Chinese populations. We serially followed up serum sIgE and sIgG4 to Der p and its components (Der p 1 and 2) in 51 Der p-sensitized children receiving guideline-based medications alone and additional 36-month AIT. The the Der p 1 and Der p 2 sIgE levels were elevated at 6 months and progressively declined from 12 months; the sIgG4 levels for Der p, Der p 1 and Der p 2 were increasing during the first year and reached a plateau thereafter; the sIgE/sIgG4 ratios for Der p 1 and Der p 2 decreased continuously from 6 through 24 months of AIT. Subgroup analysis showed that younger children (≤8years) experienced a greater increase in sIgG4 levels for Der p, Der p 1 and Der p 2 during AIT compared with older children (9-16 years). In summary, sIgE and sIgG4 to Der p 1 and Der p 2 may be more useful than those to Der p in reflecting the change in immunological reactivity during AIT. Earlier delivery of AIT may yield greater increase in sIgG4 after 36-month treatment than given later in life.
在中国人群中,关于变应原免疫疗法(AIT)期间血清中针对尘螨(Der p)变应原成分的特异性sIgE和sIgG4的纵向数据有限。我们对51名仅接受基于指南药物治疗以及另外接受36个月AIT的Der p致敏儿童,连续随访了血清中针对Der p及其成分(Der p 1和Der p 2)的sIgE和sIgG4。Der p 1和Der p 2的sIgE水平在6个月时升高,并从12个月起逐渐下降;Der p、Der p 1和Der p 2的sIgG4水平在第一年上升,此后达到平台期;在AIT的6至24个月期间,Der p 1和Der p 2的sIgE/sIgG4比值持续下降。亚组分析表明,与年龄较大的儿童(9 - 16岁)相比,年龄较小的儿童(≤8岁)在AIT期间Der p、Der p 1和Der p 2的sIgG4水平升高幅度更大。总之,针对Der p 1和Der p 2的sIgE和sIgG4在反映AIT期间免疫反应性变化方面可能比针对Der p的更有用。早期进行AIT在36个月治疗后可能比在生命后期进行产生更大的sIgG4升高。